mGluR5 antagonists: discovery, characterization and drug development.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current opinion in drug discovery & development

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 18729017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

  2008cited by this paper
• Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety

  2008cited by this paper
• Metabotropic glutamate receptors: Phosphorylation and receptor signaling

  2008cited by this paper
• Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo.

  2007cited by this paper
• Structures of the extracellular regions of the group II/III metabotropic glutamate receptors

  2007cited by this paper
• Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5.

  2007cited by this paper
• Correction of fragile X syndrome in mice.

  2007cited by this paper
• Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests.

  2007cited by this paper
• The trick of the tail: protein–protein interactions of metabotropic glutamate receptors

  2007cited by this paper
• Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688.

  2007cited by this paper
• The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention.

  2007cited by this paper
• Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

  2007cited by this paper
• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

  2007cited by this paper
• Comparative analysis of the subcellular and subsynaptic localization of mGluR1a and mGluR5 metabotropic glutamate receptors in the shell and core of the nucleus accumbens in rat and monkey

  2007cited by this paper
• A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

  2006cited by this paper
• Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia

  2005cited by this paper
• Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

  2005cited by this paper
• Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist.

  2005cited by this paper
• Adenosine A2A receptors and metabotropic glutamate 5 receptors are co‐localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N‐methyl‐d‐aspartate effects

  2005cited by this paper
• Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.

  2005cited by this paper
• Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.

  2005cited by this paper
• Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands.

  2005cited by this paper
• Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity

  2005cited by this paper
• Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers

  2005cited by this paper
• Group I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to cyclic AMP response element binding protein (CREB) through a common Ca2+‐ and protein kinase C‐dependent pathway

  2005cited by this paper
• Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynyl derivatives of pyridine: synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors.

  2005cited by this paper
• mGlu5 receptor antagonists: a novel class of anxiolytics?

  2004cited by this paper
• Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities.

  2004cited by this paper
• Group I metabotropic glutamate receptors interfere in different ways with pentylenetetrazole seizures, kindling, and kindling-related learning deficits

  2004cited by this paper
• The mGluR theory of fragile X mental retardation.

  2004cited by this paper
• In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand.

  2003cited by this paper
• Glutamate metabotropic receptors as targets for drug therapy in epilepsy.

  2003cited by this paper
• Physiological Roles and Therapeutic Potential of Metabotropic Glutamate Receptors

  2003cited by this paper
• Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors.

  2003cited by this paper
• Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins

  2003cited by this paper
• Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism

  2002cited by this paper
• Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats.

  2002cited by this paper
• The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.

  2002cited by this paper
• [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5.

  2002cited by this paper
• Distinct physiological roles of the Gq‐coupled metabotropic glutamate receptors co‐expressed in the same neuronal populations

  2002cited by this paper
• Altered synaptic plasticity in a mouse model of fragile X mental retardation

  2002cited by this paper
• Measuring drug-related receptor occupancy with positron emission tomography.

  2002cited by this paper
• mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia.

  2001cited by this paper
• Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain.

  2001cited by this paper
• Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

  2001cited by this paper
• Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors.

  2001cited by this paper
• Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats.

  2001cited by this paper
• Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective.

  2000cited by this paper
• Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.

  2000cited by this paper
• Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893).

  2000cited by this paper
• Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor

  2000cited by this paper
• Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats.

  2000cited by this paper
• Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.

  1999cited by this paper
• SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5.

  1999cited by this paper
• 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.

  1999cited by this paper
• Pharmacological agents acting at subtypes of metabotropic glutamate receptors.

  1999cited by this paper
• Antidepressants for the new millennium.

  1999cited by this paper
• Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

  1998cited by this paper
• Gastro-Oesophageal Reflux Disease

  1998cited by this paper
• The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord.

  1997cited by this paper
• Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.

  1997cited by this paper
• Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression.

  1996cited by this paper
• Metabotropic Glutamate Receptor 5 Is a Disulfide-linked Dimer*

  1996cited by this paper
• Induction or protection of limbic seizures in mice by mGluR subtype selective agonists.

  1995cited by this paper
• Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain

  1995cited by this paper
• Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5

  1995cited by this paper
• Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain.

  1993cited by this paper
• Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction.

  1992cited by this paper
• Molecular diversity of glutamate receptors and implications for brain function.

  1992cited by this paper
• Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.

  1982cited by this paper

• Quantification of [11C]ABP688 Binding to mGluR5 in Human Brain using Cerebellum as Reference Region: Biological Interpretation and Limitations

  2025cites this paper
• Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders

  2024cites this paper
• Current Radioligands for the PET Imaging of Metabotropic Glutamate Receptors

  2020cites this paper
• Group I metabotropic glutamate receptors in the primate motor thalamus: subsynaptic association with cortical and sub-cortical glutamatergic afferents

  2019cites this paper
• Dynamic changes in cerebral and peripheral markers of glutamatergic signaling across the human sleep–wake cycle

  2018cites this paper
• Computational Approaches for Therapeutic Application of Natural Products in Alzheimer’s Disease

  2018cites this paper
• mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism

  2018cites this paper
• Neuroprotective Properties of Glutamate Metabotropic Glutamate Receptors in Parkinson’s Disease and Other Brain Disorders

  2017cites this paper
• Computational approaches in target identification and drug discovery

  2016cites this paper
• VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy

  2016cites this paper
• The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders

  2016cites this paper
• 4-Aryl-3-arylsulfonyl-quinolines as negative allosteric modulators of metabotropic GluR5 receptors: From HTS hit to development candidate.

  2016cites this paper
• N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents.

  2016cites this paper
• Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression

  2015cites this paper
• NMDA receptor dysfunction in autism spectrum disorders.

  2015cites this paper
• Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats

  2015cites this paper
• Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.

  2015cites this paper
• Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.

  2014cites this paper
• Computational Methods in Drug Discovery

  2014cites this paper
• AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.

  2014cites this paper
• mGlu5 negative allosteric modulators: a patent review (2013 - 2016)

  2013cites this paper
• mGlu5 negative allosteric modulators: a patent review (2010 – 2012)

  2013cites this paper
• Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction.

  2013cites this paper
• Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep.

  2013cites this paper
• Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.

  2013cites this paper
• Future Directions in Autism Treatment

  2012cites this paper
• Pharmacological modulation of mGluR7 with AMN082 and MMPIP exerts specific influences on alcohol consumption and preference in rats

  2012cites this paper
• 3d Enantioselective Descriptors for Ligand-based Computer-aided Drug Design

  2012cites this paper
• Discovery of 2‐(2‐Benzoxazoyl amino)‐4‐Aryl‐5‐Cyanopyrimidine as Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptor 5 (mGlu5): From an Artificial Neural Network Virtual Screen to an In Vivo Tool Compound

  2012cites this paper
• Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

  2012cites this paper
• mGlu receptors and drug addiction.

  2012cites this paper
• Negative Allosteric Modulation of the mGluR5 Receptor Reduces Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Autism

  2012cites this paper
• PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

  2012cites this paper
• Overview of glutamatergic neurotransmission in the nervous system.

  2012cites this paper
• Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Negative Allosteric Modulation of the mGluR5 Receptor Reduces

  2012cites this paper
• New Small Molecule Drug Discovery for Alzheimer's Disease

  2012cites this paper
• Metabotropic glutamate receptors and drug addiction

  2012cites this paper
• Pharmacological interference with metabotropic glutamate receptor subtype 7 but not subtype 5 differentially affects within- and between-session extinction of Pavlovian conditioned fear.

  2012cites this paper
• CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor

  2011influential citation
• Triple‐Addition Assay Protocols for Detecting and Characterizing Modulators of Seven‐Transmembrane Receptors

  2011cites this paper
• Activation of Intracellular Metabotropic Glutamate Receptor 5 in Striatal Neurons Leads to Up-regulation of Genes Associated with Sustained Synaptic Transmission Including Arc/Arg3.1 Protein*

  2011cites this paper
• Invited Perspective PET imaging of metabotropic glutamate receptor subtype 5 ( mGluR 5 )

  2011cites this paper
• Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

  2011cites this paper
• Subchronic Administration and Combination Metabotropic Glutamate and GABAB Receptor Drug Therapy in Fragile X Syndrome

  2011cites this paper
• Behavioral consequences of the mGlu5 receptor antagonist MTEP in immature rats.

  2011cites this paper
• Efficacy switching SAR of mGluR5 allosteric modulators: highly potent positive and negative modulators from one chemotype.

  2011cites this paper
• mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents.

  2011cites this paper
• Recent advances in the design and development of novel negative allosteric modulators of mGlu(5).

  2011cites this paper
• Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

  2011cites this paper
• Fragile X syndrome: an update on developing treatment modalities.

  2011cites this paper
• [Pathways of research in autism].

  2011cites this paper
• (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction.

  2011cites this paper
• Exploration of structure-based drug design opportunities for mGluRs.

  2011cites this paper
• Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity

  2010influential citation
• Metabotropic glutamate receptors: their therapeutic potential in anxiety.

  2010cites this paper
• Metabotropic glutamate receptor subtype 5 antagonism in learning and memory.

  2010cites this paper
• Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists.

  2010cites this paper
• 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats.

  2010cites this paper
• Glutamate and Neurodegenerative Disease

  2010cites this paper
• Radioligands for the PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

  2010cites this paper
• Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5.

  2009cites this paper
• Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications

  2009cites this paper
• Recent progress in the discovery and development of negative allosteric modulators of mGluR5.

  2009cites this paper
• Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking.

  2009cites this paper
• Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1.

  2009cites this paper
• Ultrastructural relationships between cortical, thalamic, and amygdala glutamatergic inputs and group I metabotropic glutamate receptors in the rat accumbens

  2009cites this paper
• Tachykinin receptors as therapeutic targets in stress-related disorders.

  2009cites this paper
• Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.

  2009cites this paper